N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-1,3-thiazole-4-carboxamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-1,3-thiazole-4-carboxamide
• 化学式: C₂₂H₂₆ClN₇O₂S
• 分子量: 488.0
• InChiKey: XGDQFVSNLFJNEJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  33
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  135
• 氢给体数：
  3
• 氢受体数：
  9

文献信息

• [EN] POLYMORPHIC FORMS OF DASATINIB<br/>[FR] FORMES POLYMORPHES DE DASATINIB
  申请人：BIOCON LTD

  公开号：WO2019008555A1

  公开（公告）日：2019-01-10

  The present invention provides for the dasatinib- thymine co-crystal and dasatinib-adenine co-crystal. The present invention further provides dasatinib-butanediol solvate. The present invention further provides for crystalline dasatinib-(±) – 1, 2-Butane diol, crystalline dasatinib (R)-1, 2-Butanediol, crystalline dasatinib (S)-1, 2-Butanediol and crystalline dasatinib (±)-2, 3-Butanediol and processes for preparation thereof. The present invention also provides for a process for preparation of amorphous dasatinib using dasatinib- butanediol solvate. The present invention further provides for the preparation of anhydrous dasatinib. The present invention also provides for a process for preparation of dasatinib monohydrate from anhydrous dasatinib

  本发明提供了达沙替尼-胸腺嘧啶共晶和达沙替尼-腺嘌呤共晶。本发明进一步提供了达沙替尼-丁二醇溶剂合物。本发明还提供了结晶的达沙替尼-(±)-1,2-丁二醇，结晶的达沙替尼(R)-1,2-丁二醇，结晶的达沙替尼(S)-1,2-丁二醇和结晶的达沙替尼(±)-2,3-丁二醇及其制备方法。本发明还提供了一种利用达沙替尼-丁二醇溶剂合物制备非晶态达沙替尼的方法。本发明进一步提供了制备无水达沙替尼的方法。本发明还提供了一种从无水达沙替尼制备达沙替尼单水合物的方法。
• Polymorphic forms of Dasatinib
  申请人：BIOCON LIMITED

  公开号：US11059813B2

  公开（公告）日：2021-07-13

  The present invention provides for the dasatinib-thymine co-crystal and dasatinib-adenine co-crystal. The present invention further provides dasatinib-butanediol solvate. The present invention further provides for crystalline dasatinib-(±)-1, 2-Butanediol, crystalline dasatinib (R)-1, 2-Butanediol, crystalline dasatinib (S)-1, 2-Butanediol and crystalline dasatinib (±)-2, 3-Butanediol and processes for preparation thereof. The present invention also provides for a process for preparation of amorphous dasatinib using dasatinib-butanediol solvate. The present invention further provides for the preparation of anhydrous dasatinib. The present invention also provides for a process for preparation of dasatinib monohydrate from anhydrous dasatinib.

  本发明提供了达沙替尼-胸腺嘧啶共晶体和达沙替尼-腺嘌呤共晶体。本发明进一步提供了达沙替尼-丁二醇溶液。本发明进一步提供了结晶的达沙替尼-(±)-1，2-丁二醇、结晶的达沙替尼(R)-1，2-丁二醇、结晶的达沙替尼(S)-1，2-丁二醇和结晶的达沙替尼(±)-2，3-丁二醇及其制备工艺。本发明还提供了一种使用达沙替尼-丁二醇溶液制备无定形达沙替尼的工艺。本发明进一步提供了无水达沙替尼的制备方法。本发明还提供了一种用无水达沙替尼制备一水达沙替尼的工艺。
• POLYMORPHIC FORMS OF DASATINIB
  申请人：Biocon Limited

  公开号：EP3649126A1

  公开（公告）日：2020-05-13